Cyto Pulse Sciences, Inc.   Report issue

For profit Phase 2
Founded: Glen Burnie MD United States (1995)
Status: Acquired by Cellectis S.A. (2010)

Organization Overview

First Clinical Trial
2008
NCT00859729
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2009

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Active Ingredients

Drugs in Phase 2 Trials (3)

cyclophosphamide (cytoxan) (1 trial)

pvaxrcpsav53l (1 trial)

sargramostim (leukine) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Colorectal Neoplasms (Phase 2)

Prostatic Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 3